APA (7th ed.) Citation

Welte, T., Dellinger, R. P., Ebelt, H., Ferrer, M., Opal, S. M., Singer, M., . . . Kluge, S. (2018). Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: A randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). Intensive Care Medicine, 44(4), 438. https://doi.org/10.1007/s00134-018-5143-7

Chicago Style (17th ed.) Citation

Welte, Tobias, et al. "Efficacy and Safety of Trimodulin, a Novel Polyclonal Antibody Preparation, in Patients with Severe Community-acquired Pneumonia: A Randomized, Placebo-controlled, Double-blind, Multicenter, Phase II Trial (CIGMA Study)." Intensive Care Medicine 44, no. 4 (2018): 438. https://doi.org/10.1007/s00134-018-5143-7.

MLA (9th ed.) Citation

Welte, Tobias, et al. "Efficacy and Safety of Trimodulin, a Novel Polyclonal Antibody Preparation, in Patients with Severe Community-acquired Pneumonia: A Randomized, Placebo-controlled, Double-blind, Multicenter, Phase II Trial (CIGMA Study)." Intensive Care Medicine, vol. 44, no. 4, 2018, p. 438, https://doi.org/10.1007/s00134-018-5143-7.